Clinical Trial Detail

NCT ID NCT04195555
Title Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

Advanced Solid Tumor

histiocytic and dendritic cell cancer

Therapies

Ivosidenib

Age Groups: child adult

Additional content available in CKB BOOST